<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625726</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-403</org_study_id>
    <secondary_id>2017-A00931-52</secondary_id>
    <nct_id>NCT03625726</nct_id>
  </id_info>
  <brief_title>Rôle of the Soluble Endothelial Protein C Receptor in Cirrhosis-associated Hypercoagulability State (EXERCISE)</brief_title>
  <acronym>EXERCISE</acronym>
  <official_title>Ex Vivo Study of the Role of Soluble Endothelial Protein C Receptor in Cirrhosis-associated Hypercoagulability State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhosis is a condition in which the liver does not function properly due to long-term&#xD;
      damage. This damage is characterized by the replacement of normal liver tissue by scar&#xD;
      tissue.&#xD;
&#xD;
      The liver carries out several necessary functions, including synthesis of proteins&#xD;
      participating in blood coagulation process. Some of these proteins contribute to coagulation&#xD;
      and others make blood more fluid. In healthy people there is a balance between the two.&#xD;
&#xD;
      In cirrhotic patient, there is an imbalance inducing hypercoagulation (hypercoagulability&#xD;
      state). Cirrhotic patients are so known to be at risk of vein thrombosis (for example portal&#xD;
      vein thrombosis: clot in hepatic vein).&#xD;
&#xD;
      Mechanisms leading to this imbalance are unclear. Studies need to be completed to improve&#xD;
      patient's management.&#xD;
&#xD;
      The EPCRs (Endothelial Protein C Receptor soluble) takes part in blood coagulation process.&#xD;
      Previous studies have shown that blood levels of EPCRs are increased in patients with&#xD;
      cirrhosis.&#xD;
&#xD;
      The primary purpose of the study is to evaluate if the EPCRs could play a role in&#xD;
      cirrhosis-associated hypercoagulability state.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups will be constitued: one with cirrhotic patients, one with healthy volunteers,&#xD;
      and one with patients with hepatocellular carcinoma, a form of liver cancer (previous studies&#xD;
      have also shown that blood levels of EPCRs are increased in these patients).&#xD;
&#xD;
      All participants will undergo a unique visit at hospital. An informed consent will be&#xD;
      obtained before any related study procedures*.&#xD;
&#xD;
      * procedures: physical examination (including height, weight, waist measurement), vital signs&#xD;
      (blood pressure, heart rate, temperature), medical history, concomitant medication, blood&#xD;
      sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Exploratory, cross-sectional, case-control pathophysiology study, based on ex vivo treatment of blood samples.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin generation assay (area under the curve/ Endogenous Thrombin Potential) with thrombomodulin.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation assay parameters : peak height</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation assay parameters : lag time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation assay parameters : time to peak</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>patients with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pathophysiology study, blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pathophysiology study, blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pathophysiology study, blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thrombin generation assay (in vitro)</intervention_name>
    <description>One blood sample.</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patients with cirrhosis</arm_group_label>
    <arm_group_label>patients with hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with cirrhosis&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Male, age 18 or older&#xD;
&#xD;
          -  Cirrhosis, defined by: prothombin time ≤ 70% +/- liver dysmorphism +/- Fibroscan &gt;&#xD;
             12.5 kPa +/- histology +/- portal hypertension associated with hepatocellular&#xD;
             insufficiency&#xD;
&#xD;
          -  Cirrhosis associated with hepatitis B or C, or alcoholic liver disease, or non&#xD;
             alcoholic steato hepatitis&#xD;
&#xD;
          -  Measurable portal flow by ultrasound doppler&#xD;
&#xD;
          -  Child Pugh score A,B or C, without acute infection or acute bleeding&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Affiliation to french social security system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Known history of vein thrombosis&#xD;
&#xD;
          -  Known family history (in first-degree relative) of spontaneous thrombosis&#xD;
&#xD;
          -  Partial or complete portal system vein thrombosis&#xD;
&#xD;
          -  Uncontrolled infection after 7-day course of antibiotics&#xD;
&#xD;
          -  Anticoagulant intake&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Protected or deprived of liberty adult&#xD;
&#xD;
          -  Any medical or surgical history that could interfere with the study, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Blood transfusion within 7 days&#xD;
&#xD;
          -  Participation in a clinical trial for drug&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Male, age 18 or older&#xD;
&#xD;
          -  Body Mass Index between 18 and 30 kg/m2&#xD;
&#xD;
          -  Normal physical examination&#xD;
&#xD;
          -  Willing and able to comply with requirements of the study&#xD;
&#xD;
          -  Agree to be registered in the french national registry for healthy volunteers&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Affiliation to french social security system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Any medical or surgical history that could interfere with the study, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Participation in a clinical trial for drug&#xD;
&#xD;
          -  Protected or deprived of liberty adult&#xD;
&#xD;
          -  Known history of vein thrombosis&#xD;
&#xD;
          -  Known family history (in first-degree relative) of spontaneous thrombosis&#xD;
&#xD;
          -  Anticoagulant intake&#xD;
&#xD;
        Patients with hepatocellular carcinoma (HCC)&#xD;
&#xD;
        Inclusion criteria :&#xD;
&#xD;
          -  Male, age 18 or older&#xD;
&#xD;
          -  Histological diagnosis of HCC, or use of BCLC criteria for diagnosis&#xD;
&#xD;
          -  Treatment naïve HCC&#xD;
&#xD;
          -  Measurable portal flow by ultrasound doppler&#xD;
&#xD;
          -  For patients with cirrhosis: Child Pugh score A,B or C, without acute infection or&#xD;
             acute bleeding&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Affiliation to french social security system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Known history of vein thrombosis&#xD;
&#xD;
          -  Known family history (in first-degree relative) of spontaneous thrombosis&#xD;
&#xD;
          -  Partial or complete portal system vein thrombosis&#xD;
&#xD;
          -  For patients with cirrhosis: uncontrolled infection after 7-day course of antibiotics&#xD;
&#xD;
          -  Anticoagulant intake&#xD;
&#xD;
          -  Protected or deprived of liberty adult&#xD;
&#xD;
          -  Any medical or surgical history that could interfere with the study, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Blood transfusion within 7 days&#xD;
&#xD;
          -  Prior treated malignancy within the previous 2 years (except basal cell and squamous&#xD;
             cell skin cancer, and superficial bladder cancer)&#xD;
&#xD;
          -  Participation in a clinical trial for drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armand ABERGEL</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>04 73 75 49 63</phone>
    <email>drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise LACLAUTRE</last_name>
      <phone>04 73 75 49 63</phone>
      <email>drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Armand ABERGEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien LEBRETON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas SINEGRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine LAMBLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léon MUTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille TEILHET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud REYMOND</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile CAMPOS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>hypercoagulability</keyword>
  <keyword>thrombin generation assay</keyword>
  <keyword>soluble Endothelial Protein C Receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

